PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate
Authors
Keywords
-
Journal
CLINICAL SCIENCE
Volume 132, Issue 10, Pages 1075-1083
Publisher
Portland Press Ltd.
Online
2018-05-04
DOI
10.1042/cs20180040
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
- (2018) Gerald F Watts et al. EUROPEAN HEART JOURNAL
- The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab
- (2017) Byambaa Enkhmaa et al. JOURNAL OF LIPID RESEARCH
- A Test in Context: Lipoprotein(a)
- (2017) Sotirios Tsimikas JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9
- (2017) Rocco Romagnuolo et al. PLoS One
- Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective
- (2016) Gissette Reyes-Soffer et al. CIRCULATION
- Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismClinical Perspective
- (2016) Gerald F. Watts et al. CIRCULATION
- PCSK9 Association With Lipoprotein(a)Novelty and Significance
- (2016) Hagai Tavori et al. CIRCULATION RESEARCH
- Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a)Novelty and Significance
- (2016) Monika Sharma et al. CIRCULATION RESEARCH
- Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC/MS/MS
- (2016) Mikaël Croyal et al. JOURNAL OF LIPID RESEARCH
- SRM-based measurements of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) kinetics in nonhuman primate serum
- (2016) Fang Xie et al. Bioanalysis
- Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic PatientsSignificance
- (2015) Mikaël Croyal et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
- (2015) Rocco Romagnuolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Rhesus monkey (Macaca mulatta) lipoprotein(a) and apolipoprotein(a): high frequency of small size apolipoprotein(a) isoforms
- (2015) Byambaa Enkhmaa et al. JOURNAL OF MEDICAL PRIMATOLOGY
- PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels
- (2015) A. David Marais et al. PHARMACOLOGY & THERAPEUTICS
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
- (2013) Evan A. Stein et al. CIRCULATION
- Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk
- (2013) Amit V. Khera et al. CIRCULATION
- Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
- (2013) Hagai Tavori et al. CIRCULATION RESEARCH
- Lipoprotein(a): resurrected by genetics
- (2013) F. Kronenberg et al. JOURNAL OF INTERNAL MEDICINE
- Regulation of ApoB Secretion by the Low Density Lipoprotein Receptor Requires Exit from the Endoplasmic Reticulum and Interaction with ApoE or ApoB
- (2008) Daniel A. Blasiole et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now